TESARO,Inc. (NASDAQ:TSRO) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security
Holders.
The 2017 Annual Meeting of Stockholders (the Annual Meeting) of
TESARO,Inc. (the Company) was held on May11, 2017. As of March14,
2017, the date of record for determining the stockholders
entitled to vote on the proposals presented at the Annual
Meeting, there were 53,801,752 shares of Company common stock
issued and outstanding and entitled to vote at the Annual
Meeting. The holders of 50,118,797 shares of the Companys issued
and outstanding common stock were represented in person or by
proxy at the Annual Meeting, constituting a quorum. The proposals
are described in detail in the Companys definitive proxy
statement filed with the Securities and Exchange Commission on
April7, 2017 (the Proxy Statement). The vote results detailed
below represent final results as certified by the Annual Meetings
inspector of elections.
Proposal 1
The Companys stockholders elected the following persons, who were
listed in the Companys proxy statement for the Annual Meeting, to
the Companys Board of Directors to hold office until the next
annual meeting of stockholders or until their successors are
elected and qualified or until his or her earlier death,
resignation or removal:
|
|
VotesFor |
|
VotesWithheld |
|
BrokerNon-Votes |
|
|
|
Leon O. Moulder,Jr. |
47,666,903 |
14,274 |
2,437,620 |
||||
|
Mary Lynne Hedley, Ph.D. |
47,179,310 |
501,867 |
2,437,620 |
||||
|
David M. Mott |
47,460,790 |
220,387 |
2,437,620 |
||||
|
Lawrence M. Alleva |
47,597,696 |
83,481 |
2,437,620 |
||||
|
James O. Armitage, M.D. |
47,617,156 |
64,021 |
2,437,620 |
||||
|
Earl M. (Duke) Collier,Jr. |
47,563,427 |
117,750 |
2,437,620 |
||||
|
Garry A. Nicholson |
47,617,573 |
63,604 |
2,437,620 |
||||
|
Arnold L. Oronsky, Ph.D. |
47,592,291 |
88,886 |
2,437,620 |
||||
|
Kavita Patel, M.D. |
47,616,325 |
64,852 |
2,437,620 |
||||
|
Beth Seidenberg, M.D. |
47,617,518 |
63,659 |
2,437,620 |
Proposal 2
The Companys stockholders approved, by non-binding vote, the
Companys executive compensation. The votes regarding this
proposal were as follows:
|
VotesFor |
|
VotesAgainst |
|
Abstentions |
|
BrokerNon-Votes |
|
47,080,406 |
594,222 |
6,549 |
2,437,620 |
Proposal 3
The Companys stockholders ratified the appointment of Ernst
Young,LLP as the Companys independent registered public
accounting firm for the fiscal year ending December31, 2017. The
votes regarding this proposal were as follows:
|
VotesFor |
|
VotesAgainst |
|
Abstentions |
|
BrokerNon-Votes |
|
50,040,986 |
72,920 |
4,891 |
|
About TESARO, Inc. (NASDAQ:TSRO)
TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042. TESARO, Inc. (NASDAQ:TSRO) Recent Trading Information
TESARO, Inc. (NASDAQ:TSRO) closed its last trading session down -0.73 at 142.00 with 710,546 shares trading hands.
